Phase II trial of ifosfamide/carboplatin/etoposide/Rituxan [rituximab] followed by Zevalin [ibritumomab tiuxetan Y-90] in the treatment of patients with relapsed/refractory intermediate grade B-cell lymphoma

Trial Profile

Phase II trial of ifosfamide/carboplatin/etoposide/Rituxan [rituximab] followed by Zevalin [ibritumomab tiuxetan Y-90] in the treatment of patients with relapsed/refractory intermediate grade B-cell lymphoma

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Jun 2015

At a glance

  • Drugs Ibritumomab tiuxetan (Primary) ; Carboplatin; Etoposide; Ifosfamide; Rituximab
  • Indications Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Dec 2010 Actual end date (Aug 2005) added as reported by ClinicalTrials.gov.
    • 15 Oct 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 01 Dec 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top